source
- Lilly's retatrutide outperforms Ozempic in weight loss and blood sugar reduction in head-to-head diabetes trialEli Lilly reported that its experimental drug retatrutide showed greater efficacy than Novo Nordisk’s Ozempic in a large diabetes trial. After 80 weeks, participants receiving the highest dose of…
- FDA outlines pathway for approval of personalized gene-editing therapiesThe U.S. Food and Drug Administration released a set of recommendations describing how developers can pursue regulatory approval for gene-editing treatments that are customized to a single patient’…